Q-omics provides the consensus-scored PPT2 profile across patient tissues and cancer cell-line models. PPT2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PPT2 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, PPT2 RNA expression shows 19,603 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, THCA, and ACC as cancer lineages where PPT2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPT2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPT2 survival associations across molecular data types. PPT2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPT2 RNA expression–survival associations across cancer types. High PPT2 expression shows unfavorable associations in HNSC, LUAD and LIHC, but favorable associations in SCLC, KIRC and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PPT2 RNA expression.
This table summarizes PPT2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PPT2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPT2 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in LIHC, LUSC and COAD. The THCA box plot shows higher PPT2 RNA expression in normal versus tumor tissue (log2 FC = −0.445, t-test p < 0.001).
This table shows molecular features associated with PPT2 in patient tissues and cancer cell lines. In patient samples, PPT2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPT2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
